Previous 10 | Next 10 |
On Nov 29, KRYS reported positive topline results from their pivotal phase 3 trial of "VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa (DEB). Pivotal GEM-3 trial met its primary and secondary endpoints, i.e. the differences in complete wound healings between treatmen...
Krystal Biotech (NASDAQ: KRYS) saw its shares climb more than 77% this week, according to data provided by S&P Global Market Intelligence . The stock was only at $39.81 at Friday's close, then opened at $91.20 on Monday and climbed to as high as $102.99. While the stock has ...
Shares of the gene therapy specialist Krystal Biotech (NASDAQ: KRYS) are down by 13.6% as of 1:38 p.m ET Wednesday afternoon. The biotech's shares are sinking today in response to a $200 million public offering. More specifically, Krystal announced yesterday that it plans an off...
Krystal Biotech (NASDAQ:KRYS) has priced its public offering of ~2.7M shares of common stock, at $75.00/share, for expected gross proceeds of ~$200M. Underwriters' over-allotment is an additional 400K shares. All of the shares will be sold by the Company other than up to 200K that may be sold...
PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its com...
Positive results were obtained from the phase 3 GEM-3 study using VYJUVEK for the treatment of patients with dystrophic Epidermolysis Bullosa. STAR-D technology platform is highly efficient in using an engineered non-encoding HSV-1 viral vector to deliver a large gene or multiple gene...
Monday saw a substantial rebound following the Omicron-related sell-off that took place going into the weekend. The recovery included the oil sector, with Devon Energy (NYSE:DVN), Diamondback Energy (NASDAQ:FANG), APA Corp. (NASDAQ:APA) and Baker Hughes (NYSE:BKR) all posted gains on the sess...
Krystal Biotech (NASDAQ:KRYS) trades 5.4% higher after hours on commencing a $200M underwritten public offering of its common stock; company and certain selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional $30M of share...
PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock. The Company and ...
Shares of Krystal Biotech Inc ( NASDAQ: KRYS ) more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its primary and secondary endpoint According to Krystal Biotech, the study in...
News, Short Squeeze, Breakout and More Instantly...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U....
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...